Effects of Hypothermia vs Normothermia on Societal Participation and Cognitive Function at 6 Months in Survivors After Out-of-Hospital Cardiac Arrest

Abstract

ImportanceThe Targeted Hypothermia vs Targeted Normothermia After Out-of-Hospital Cardiac Arrest (TTM2) trial reported no difference in mortality or poor functional outcome at 6 months after out-of-hospital cardiac arrest (OHCA). This predefined exploratory analysis provides more detailed estimation of brain dysfunction for the comparison of the 2 intervention regimens.ObjectivesTo investigate the effects of targeted hypothermia vs targeted normothermia on functional outcome with focus on societal participation and cognitive function in survivors 6 months after OHCA.Design, Setting, and ParticipantsThis study is a predefined analysis of an international multicenter, randomized clinical trial that took place from November 2017 to January 2020 and included participants at 61 hospitals in 14 countries. A structured follow-up for survivors performed at 6 months was by masked outcome assessors. The last follow-up took place in October 2020. Participants included 1861 adult (older than 18 years) patients with OHCA who were comatose at hospital admission. At 6 months, 939 of 1861 were alive and invited to a follow-up, of which 103 of 939 declined or were missing.InterventionsRandomization 1:1 to temperature control with targeted hypothermia at 33 °C or targeted normothermia and early treatment of fever (37.8 °C or higher).Main outcomes and measuresFunctional outcome focusing on societal participation assessed by the Glasgow Outcome Scale Extended ([GOSE] 1 to 8) and cognitive function assessed by the Montreal Cognitive Assessment ([MoCA] 0 to 30) and the Symbol Digit Modalities Test ([SDMT] z scores). Higher scores represent better outcomes.ResultsAt 6 months, 836 of 939 survivors with a mean age of 60 (SD, 13) (range, 18 to 88) years (700 of 836 male [84%]) participated in the follow-up. There were no differences between the 2 intervention groups in functional outcome focusing on societal participation (GOSE score, odds ratio, 0.91; 95% CI, 0.71-1.17; P = .46) or in cognitive function by MoCA (mean difference, 0.36; 95% CI,−0.33 to 1.05; P = .37) and SDMT (mean difference, 0.06; 95% CI,−0.16 to 0.27; P = .62). Limitations in societal participation (GOSE score less than 7) were common regardless of intervention (hypothermia, 178 of 415 [43%]; normothermia, 168 of 419 [40%]). Cognitive impairment was identified in 353 of 599 survivors (59%).ConclusionsIn this predefined analysis of comatose patients after OHCA, hypothermia did not lead to better functional outcome assessed with a focus on societal participation and cognitive function than management with normothermia. At 6 months, many survivors had not regained their pre-arrest activities and roles, and mild cognitive dysfunction was common.Trial RegistrationClinicalTrials.gov Identifier: NCT02908308

Telephone-based evaluation of cognitive impairment and mood disorders in cardiac arrest survivors with good neurologic outcomes: a retrospective cohort study

“…Based on HADS scale, the prevalence of anxiety and depression among OHCA survivors are previously reported to be about 20–30% 28 . Even though the screening tools that we used were not validated in patients with OHCA, the telephone versions of Mini MoCA and AD-8 for cognitive impairment and PHQ-9 and HADS for mood disorders might be feasible OHCA screening tools for long-term follow-up 30 . However, with regard to cognitive test, AD-8 could yield too many false positives when compared to a performance-based tool such as the Mini MoCA and should be interpreted cautiously.…”

A nomogram based on neuron-specific enolase and substantia nigra hyperechogenicity for identifying cognitive impairment in Parkinson’s disease

“…Global cognitive function was evaluated using MoCA according to the critiques and recommendations set by the International Parkinson and Movement Disorders Society ( 18 ). The overall MoCA score ranges from 0 to 30, with a value below 26 indicating CI ( 20 ). The participants were then classified into two groups: PD patients with normal cognition (PD-NCI) and PD patients with CI (PD-CI).…”

Iron and erythropoietin to heal and recover after intensive care (ITHRIVE): A pilot randomised clinical trial

“…At Day 90, following randomisation, site research coordinators contacted participants by phone to check whether hospital readmission had occurred, whether there had been nonprotocol study drug administration, any adverse events had occurred, and conduct a quality-of-life survey using EuroQuol 5D-5L (EQ5D5L) and a cognitive function survey using the telephone version Montreal Cognitive Assessment (T-MOCA). 23 As part of the process of consumer input into the pivotal trial design, all pilot participants were asked to consider the minimum number of additional days at home until day 90 that would be of value to them. This was recorded as the participant-reported DAH 90 minimum clinically important difference.…”